Shorted
Dimerix logo
DXB

Dimerix

Pharmaceuticals, Biotechnology & Life Sciences

Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred pharmaceutical products for global markets. Their focus is on identifying and developing drugs for areas with unmet needs, particularly in inflammatory diseases affecting the kidney and lungs.

Short position

short percentage0.05%
reported shorts271K
shares on issue600.397M

Dimerix (ASX:DXB) has 0.05% of its shares on issue reported as short positions as of 22 Sept 2026, or about 270,986 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.50% in March 2025. DXB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Dimerix (DXB) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
3d ago

Is Dimerix (ASX:DXB) Long-Term Kidney Data Building Momentum?

Highlights Dimerix said the earliest patient in its lead kidney disease programme has completed a multi-year stretch of continuous treatment. Almost all eligible patients who finished the blinded phase of its pivotal trial chose to continue into the open-label extension. The pivotal late-stage study remains ongoing, with the adult cohort fully recruited across many countries. Dimerix (ASX:DXB) announced this week that the earliest patient in its lead kidney disease programme has now completed...

Continue reading
Kalkine
Neutral
7 Sept

Why Is Dimerix (ASX:DXB) Joining ASX Rebalance Focus?

Highlights Dimerix is in focus after its latest market disclosure clarified current operating priorities. The news is relevant to operating progress, funding capacity and market access, with delivery and financial resilience central to the market reading. Independent reporting adds context while the company material remains the primary factual reference. Dimerix (ASX:DXB) is drawing current ASX attention after its latest clinical update added detail about its operating direction and near term...

Continue reading
Kalkine
Neutral
14 July

Dimerix (ASX:DXB): Why Is It Back on the Penny Stock Radar?

Highlights Dimerix is returning to focus as clinical milestones become the clearest measure of progress across its kidney disease program. Funding discipline, trial execution and risk control are shaping how the companys biotechnology story is being assessed. Penny-stock coverage is narrowing towards measurable evidence, balance sheet resilience and careful use of financial resources. Australian shares have opened with a cautious and selective tone as oil volatility, steadier banking acti...

Continue reading
Kalkine
Neutral
28 Apr

Why Is (ASX:DXB) Dimerix Advancing Its Phase 3 Strategy?

Highlights Phase 3 pathway gains stronger clarity Trial design aligned with regulators Program momentum remains steady Dimerix continues to refine its late-stage kidney disease program, strengthening clinical confidence and aligning with regulatory expectations while progressing toward a decisive trial outcome. The biotech landscape often shifts on subtle developments rather than headline-grabbing breakthroughs. One such example is Dimerix Ltd (ASX:DXB), which has recently taken a measu...

Continue reading